Chelsea Therapeutics to cut jobs, CEO resigns
July 10 (Reuters) - Chelsea Therapeutics International Ltd said it plans to "significantly reduce" its workforce and explore strategic options, barely a week after the U.S. health regulator asked for an additional trial to approve its hypotension drug Northera.
The company also said Chief Executive Simon Pedder will step down effective immediately.
The job cut is expected to be completed in the third quarter of 2012 and will result in annual salary reductions of at least $3.5 million, excluding any one-time restructuring charges.
- Israel pummels Gaza; Kerry steps up diplomatic push |
- With sales sputtering, Apple's iPad looks to IBM alliance
- Ukraine war crimes trials a step closer after Red Cross assessment
- Five held in China food scandal probe, including head of Shanghai Husi Food
- Rebels likely downed Malaysian jet 'by mistake': U.S. officials